The IntelliGenome team has developed the first molecular diagnostic detection assay in the world using CRISPR technology to detect low abundance nucleic acid in small volume blood samples. We have also developed a high-efficiency DNA polymerase-based and thermostable protein-enhanced CRISPR fluorescence detection system, and further developed an ultra-sensitive approach to detect TB cell-free DNA in blood samples, which is an isolation-free, multiplex recombinase polymerase amplification (RPA)-CRISPR detection assay and a portable device to read point of care (POC) test results.

Global IVD distribution network. Delivering a 510k FDA approved Drugs of Abuse testing portfolio in the US market in collaboration with EuroMed USA. Commercializing a blood-based TB assay run with PCR and CRISPER technology which is scheduled for submission to the FDA for Breakthrough Device Designation in Q3 2024.

Corgenix, founded in 1990, is medical diagnostics company based in Broomfield, Colorado. We are a full service partner to the Diagnostics and Pharmaceutical industry, offering a broad and unique array of products and capabilities. We are experts in the development, tech transfer, registration, manufacturing and commercialization of specialty diagnostics tests.For contract development, what makes us different from others is that we are platform agnostic. What this means is that we will develop tests on any platform, depending on the requirements of our client. We will develop on any platform that meets the technical, clinical and commercial requirements of your customer. In addition, we pride ourselves on our project management skills and our robust quality management system. All of our development projects are conducted under strict design controls, with a focus on meeting promised timelines and budgets. We also help our partners with FDA and international registration processes and commercialization. In addition, we provide assay validation services, reproducibility and bridging studies.For contract manufacturing, quality is the key differentiator. We are ISO-13485:2016, an FDA registered facility and GMP compliant. We produce private label tests as well as our own product lines in our Broomfield facility.Corgenix also has an on-site CAP/CLIA certified laboratory. Whether you need support for research or clinical trial testing or contract clinical testing services, we are here to serve.Above all, we believe in clear communication and transparency. We take a cross-functional team approach to our projects, fully engaging with our clients throughout the project. What do you need? Let’s see how we can help! Please contact us (anchor tag to contact info at bottom of page) to see how we can support your business strategy!

Scientific laboratory is a full service clinical lab that serviced the long term care, substance abuse, detox and recovery space, mental health facilities and pain management clinics.• Revenue growth of $326,000 YOY for blood 2017, $344,400 YOY 2018• Overall accession growth of 3,824 FP/GP/Int. Med. Call points (non-treatment center)• Grew toxicology revenue by $730,000 YOY 2017, $613,000 YOY 2018• 9 reps stayed $8,600 under expense budget of $100,000 • Grew revenue per accession from 13.4% to 14.6% over 2 years• Passed review by United Health Care group, flag removed for payments in 2018• Sold company

Launched pharmacogenetics (2012) and advanced lipids (2014). Developed programs based on clinical, procedural and financial utility. • Grew daily patient encounters by 60% YOY, revenue per requisition by 63% YOY • Added 3 clients per month per territory in lipids (4 territories total) 200 tests per new client • Opened patient service center 31% under budget, grew draws 21% month over month for 6 months.• Grew tests per requisition from 6 to 15 YOY, revenue per requisition to over $300• Innovation cut turn around time from 11 to 5 days through auto reflex program. • PGx team grew market from 0 to 214 submitting physician’s in 1 year• Grew PGx volume from 0 to 19,717 tests by end of 2013, revenue of $10,026,396 • Program continued to expand after federal and commercial reimbursement ended• Championed investigation, on-boarding and adoption of the Prosigna platform by Nanostring• Signed company first lab service agreements with LipoScience, Boston heart and Cleveland Heart.• Company assets sold off and shut down

ResponseDX: Lung™, ResponseDX: Colon™, ResponseDX: Gastric™, ResponseDX: Melanoma™—to help physicians with therapeutic treatment decisions for patients with non-small cell lung cancer (NSCLC) EGFR, EML4-ALK, c-Met, ROS-1, PI3Kinase, KRAS, ERCC-1; Colorectal Cancer (CRC) KRAS, BRAF, NRAS, PI3, MSI, c-Met, PI3Kinase, ERCC1, EGFR, TS; Gastric Cancer (GC) HER2; and Melanoma BRAF. • Added 1 new account for first 8 months, grew tests ordered by 546 YOY• Grew total panels ordered by 11% resulting in revenue growth of $313,000• 112% quota attainment YOY in 2011, quota attainment 104% YOY in 2012• Ended $12,189.00 under expense budget YOY 2012 through efficient territory mgmt.Related Targeted Therapies:Erlotinib (Tarceva), Pemetrexed (Alimta), Cetuximab (Erbitux), Bevacizumab Injection (Avastin), Carboplatin (Platinum), Cisplatin (Platinum), FOLFOX (FOL– Folinic acid (leucovorin), Fluorouracil (5-FU), OX – Oxaliplatin (Eloxatin), FOLFIRI (IRI- Irinotecan), Gemcitabine, Crizotinib (XALKORI®), Vemurafenib (Zelboraf)

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services. CGI’s cutting-edge proprietary tests and state- of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state of the art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. • Grew flow cytometry submissions by 45 cases• Grew Zap-70/CD38 by 38 cases• Increased BRAF submissions for lung by 103 cases, 100% growth YOY• Increased CLL complete submissions by 28 cases, 100% growth YOY• Grew full case referrals by 67% YOY, 18 total cases• Grew revenue by $1,026.000 in 16 physician pathology practice in South Florida

LabCorp is a full service national laboratory servicing all specialties and testing for all disease statesLabCorp, Eastern U.S. (U.S. Labs/Esoterix/Dianon)Regional Director of Business Development Directed team of 10 sales representatives covering 11 states • Grew team from 4 to 10 associates. Hired, trained and managed 6 new reps plus 4 tenured reps in $42 Million dollar territory.• Increased histology volume by 11% territory wide • Increased tech-only IHC by 655 per month for 4% growth YOY 2009• Increased Virtual Image (breast markers only) by 3% per territory on average• Increased flow cytometry cases by 4% per territory on average over 2 years• Increased cytogenetics cases by 4% per territory on average over 2 yearsDistrict Manager, Florida Managed 4.7-million-dollar territory in SW Florida • Grew full case referrals by 11% YOY in Florida and S. Georgia 2007• Increased full case referral revenue by 9% YOY in Florida and S. Georgia 2007• Increased circulating tumor cell submissions by 237 cases in 2007• Molecular test case growth of 16% YOY, $600,000 revenue increase YOY• Earned lead speaker platform for Florida Society of Pathology Winter 2007• Promoted to East Coast Regional Manager of Business Development 2008SALES REPRESENTATIVE, Florida Covered all of Florida excluding South East Florida• Gem Club winner 2006, promoted to DM 2007• Launched FLT-3, JAK-2 for Polycythemia Vera patients, grew accessions by 16 in fiscal year 2006• Grew revenue $840,000 YOY 2006, ($37,000 Q4 bonus check)• 103% quote attainment in 2005• 101% quota attainment in 2004 on 2.2 million dollar territory • 106% quota attainment in 2003 after inheriting an underperforming territory• 100% quota attainment in 2002 after losing top account to tech flow program

Polymedco, Inc. operates as a marketing and distribution company in the clinical laboratory marketplace. The company offers reagents/kits, including chemistry tests in various platforms and packaging configurations, hematology tests, point of care diagnostics, and research-only products; and instruments, such as bench top analyzers, chemistry analyzers, automated immunoassay-based fecal occult blood analyzers for the detection of human hemoglobin in fecal specimens, and automated sedrate systems that provide ESR results, as well as a small bench top instrument that measures Hemoglobin A1c, Microalbumin, and CRP. Polymedco, Inc. was founded in 1980 and is based in Cortlandt Manor, New York.• President’s Club Award Winner 1999• Led company with 2200 BTA Stat test submissions for recurrent bladder cancer• Grew specialty chemistries with 16 new HCA hospitals worth $276,000 YOY growth focusing on direct LDL, fructosamine, microalbumin and HsCRP• 104% or better quota attainment for 5 straight years.